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Abstract  
Objectives Non-invasive tests for early detection of lung cancer are an important unmet clinical 
need. CIZ1b plasma biomarker can discriminate stage 1 lung cancer from within high-risk groups 
with clinically useful accuracy, with ROC AUCs in excess of 0.9 for two independent retrospective 
cohorts, and could therefore meet this need. Our aim was to characterise the native state of the 
biomarker and develop a quantitative immunoassay. 
Design and methods Selective denaturation, preparative electrophoresis and mass 
spectrometry of human plasma was used to characterise the biomarker and interaction partners. 
A sandwich ELISA was generated, and specificity for CIZ1b biomarker tested on lung cancer 
patient plasma. 
Results CIZ1b biomarker is a denaturation-resistant complex between a C-terminal fragment of 
CIZ1 bearing the CIZ1b epitope specified by alternative splicing of exon14, and fibrinogen alpha 
chain. Reconstitution of the biomarker epitope with purified fibrinogen and CIZ1b, but not CIZ1a 
(non-alternatively spliced exon 14) confirmed the specificity of the results. The endogenous 
complex is highly stable in lung cancer plasma and can be quantified by pairing of a CIZ1b exon-
junction specific antibody with detection of fibrinogen. Application of this sandwich ELISA to a 
prospectively collected development set of plasmas reveals the same level of accuracy as the 
western blot used to validate the discriminatory capability of the biomarker.  
Conclusions Unexpected and unusual molecular structure of CIZ1b in native plasma has 
complicated immunoassay design, and delayed translation of this promising biomarker. However, 
CIZ1b can now be measured using a high-throughput, hospital-friendly sandwich ELISA format, 
overcoming an important barrier to further clinical development and application of this blood test 
for early stage lung cancer. 
 
 
 
Key words Lung cancer, CIZ1b, blood test, immunoassay, biomarker. 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Immunoassay for CIZ1b lung cancer biomarker 
 3 
Introduction  A unique protein epitope, created by alternative-splicing of the CIZ1 gene, is 
present in the plasma fraction of blood from patients with lung cancer, making it a strong 
candidate for high impact, high throughput early detection of lung cancer. We showed previously 
that detection of this b-variant form of CIZ1 (CIZ1b) is sensitive enough to allow accurate 
identification of patients with stage 1 disease, evidenced by an archived set of cases and 
matched high-risk controls, including benign lung nodules, inflammatory diseases of the lung, 
asthma, COPD and age-matched smokers (1). Biomarker detection is reproducible and 
quantifiable in less than a microliter of plasma by western blot, giving very favourable outputs in 
two independent archived cohorts, with 170 and 160 samples respectively. For set 1, mean 
CIZ1b level in individuals without diagnosed tumours established a threshold that correctly 
classified 98% of small cell lung cancers (SCLC) and non-SCLC patients (receiver operator 
characteristic AUC 0.958). Within set 2, comparison of stage 1 non-SCLC with asymptomatic 
age-matched smokers, or individuals with benign lung nodules, correctly classified 95% of 
patients (AUCs 0.913, 0.905), with overall specificity of 76%, and 71% respectively. Moreover, 
using the mean of controls in set 1, we achieved 95% sensitivity among stage 1 non-SCLC 
patients in set 2 with 74% specificity, demonstrating the robustness of the classification. Thus, 
CIZ1b performs with clinically useful accuracy, and could potentially satisfy the unmet need for a 
circulating biomarker for early detection of lung cancer.  
However, clinical development of this promising blood test requires translation of western 
blot-based analysis of denatured samples, into a high-throughput immunoassay format, 
compatible with near native epitopes. The unusual and complicated composition of the biomarker 
has limited timely translation to immunoassay format, however based on detailed analysis of its 
identity in lung cancer patient plasma we now report development of a quantitative sandwich 
ELISA. We also report underpinning information on biomarker stability, and unexpected findings 
about the native format of CIZ1b, and its interaction partners in human blood. The data presented 
here defines the CIZ1b plasma biomarker as a small CIZ1 fragment spanning the exon 14b/15 
junction stably complexed with fibrinogen alpha chain, and has lead to proof of concept validation 
of a quantitative sandwich ELISA that can detect the CIZ1b/fibrinogen alpha complex in lung 
cancer patients, via a simple immunoassay of blood.  
In intact cells, the CIZ1 protein is part of the nuclear matrix (NM), a biochemically defined 
fraction that resists extraction from the nucleus and which is thought to play a role in spatially 
organising nuclear process such as DNA replication (2). CIZ1 plays a role in DNA replication via a 
mechanism that involves tethering regulators of DNA replication, including cyclins, to the NM (3, 
4). Since it was first identified (5), CIZ1 has been linked with neurological disorders including 
Alzheimer’s disease (6) and cervical dystonia (7), and a rapidly growing range of cancers 
including the pediatric tumours medulloblastoma (8) and Ewings tumour (9), and more common 
adult onset cancers including breast (10), lung (1), colon (11), prostate (12) and liver cancers 
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(13), in some cases showing promise as independent prognostic (11) or diagnostic indicators (1), 
and in others implicated in the proliferation characteristics of cultured cancer cells (14, 15). 
Notably, CIZ1 transcripts are alternatively spliced to yield 25 (Aceview 2012) or more (16) 
variants. Most are not fully characterised but some, including CIZ1b, appear to be inaccurate 
splicing events expressed only in tumours (1), while other ‘normal’ variants are associated with 
disease when expressed in the wrong developmental context (9, 17). Our previous functional 
analysis of CIZ1 informed our understanding of the altered forms detected in lung cancer 
libraries, and led us to focus on CIZ1b, and then to identify CIZ1b protein in blood plasma. 
However, while we now understand much about CIZ1s function inside the nucleus, we do not yet 
know whether circulating CIZ1b has biological significance in the blood, other than as a very 
potent marker of malignant lung tumours.  
 
Results 
Biomarker characterisation Published analysis of CIZ1b was carried out with anti-peptide rabbit 
polyclonal antibody 2B, which was raised against a short unique peptide spanning the 
alternatively spliced 14b-15 junction (Fig.1A), with sequence DEEEIEVRSRDIS (junction 
indicated by underlined valine). The strategy for generation, validation and purification was 
described previously (1). The western blot reactivity profile for 2B includes a 65-70kDa entity in 
SDS-PAGE of plasma from lung cancer patients, plus a 55kDa entity in plasma from all people 
(Fig.1B, and Fig.S1A). The cancer-specific 65-70kDa species is the CIZ1b biomarker that is 
referred to here and previously (1). Crucially, unlike plasma, we were unable to detect this protein 
in serum samples from the same lung cancer patients (Fig.1C), suggesting that CIZ1b biomarker 
is sequestered in coagulated blood.  
Notably, the 55kDa generic band co-migrates with CIZ1 species detected with anti-CIZ1 
exon 17 antibodies, and an anti-CIZ1 exon 8 antibody (Fig.1B), identifying the 55kDa species as 
a variant or proteolytic fragment of full-length hCIZ1 (which has a predicted full length MW of 
99kDa, NCBI Reference Sequence: NM_012127.2). The width of the bands detected via exon 8 
and exon 17 is different, possibly because the exon 8 epitope lies within an alternatively spiced 
region, while detection via exon 17 would reveal species with or without alternative splicing at 
exon 8. Thus, at least one form of the CIZ1 protein is present in the circulatory system in cancer 
and non-cancer plasma samples alike, suggesting it to be part of normal physiology.  
Exon 17 and exon 8 epitopes are not present in the 65-70kDa species recognised by 
CIZ1b antibody 2B in cancer patients, which means that sequences both upstream and 
downstream of the CIZ1b epitope are missing from this protein, raising questions about its 
identity. The data suggest that the 65-70kDa species is either a complicated CIZ1 splice variant, 
or an SDS-stable complex between a CIZ1b fragment of CIZ1 and a carrier protein (Fig.1D). 
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In order to understand the relationship between cancer-specific 65-70 and generic 55, 
and to ask whether 55 i) incorporates the 14b/15 junction or ii) is detected by 2B via epitopes that 
immediately flank the junction, we generated a further set of rabbit antibodies using the same 
immunisation protocol as for 2B. This yielded antibody 043, which cleanly and uniquely reacts 
with the 65-70kDa band in cancer patients (Fig.1B, Fig.S1A, B). Thus 043 is a much cleaner 
detection tool than 2B with potential for application in other assay formats, including ELISA. Lack 
of recognition of the 55kDa species suggests less contribution of junction flanking sequences to 
its epitope compared to 2B, and suggests that the 55kDa species does not contain the CIZ1b 
junction. 
Direct comparison of the ability of these two antibodies to discriminate lung cancer 
patients by western blot shows them both to be discriminatory, with a high degree of correlation 
(Fig.1E), though notably they do not share exactly the same profile across plasma test set A. 
Thus, there is some variation in their epitopes but a common ability to discriminate patients with 
lung cancer from those without. There is also a small advantage in integrating their output to 
maximise selectivity (raw data in SI Data set 1). 
 
Stability The published (1) and current data support the assertion that CIZ1b is a potent 
circulating biomarker for lung cancer with significant potential for application in clinical practise. 
However to realise this potential, it must be robust enough to withstand variations in sample 
processing and collection regimes that occur in busy hospitals. Therefore, we tested the stability 
of the 65-70kDa cancer-selective CIZ1b species in plasma and whole blood, and compared it with 
the 55kDa species, using antibody 2B. The data show stability in isolated plasma over at least 6 
hours when incubated at 37
O
C, with gradual decay in both species thereafter (Fig.S2A). Similarly, 
there was relatively little change during an hour at temperatures up to 50
O
C (Fig.S2B), and 
stability over at least 3 freeze-thaw cycles (Fig.S2C). Furthermore, when whole blood was left on 
the bench for up to 24 hours prior to fractionation there was no loss of signal (Fig.S2D), all of 
which indicate it to be a robust biomarker suitable for application in a range of clinical settings. 
 
Complex dissociation Under native conditions both 2B and 043 detect a complex in excess of 
720kDa that co-migrates with an abundant protein in plasma (shown for 043 in Fig.S3A), but 
there is very little discrimination between cancer and non-cancer plasmas. Upon further 
separation through a second dimension under denaturing conditions the cancer-specific 65-
70kDa species is revealed and (for 2B) separated from the 55kDa generic band (Fig.S3B). Thus, 
cancer-specific detection of CIZ1b in a completely native immunoassay format is unlikely even 
with 043. We therefore dissected out the three major denaturing influences (heat, SDS, reducing 
agent) that reveal cancer-specific signal and evaluated their effect on the mobility and 
discrimination of CIZ1b by 043. This showed that 1% SDS shifts the major reactive species from 
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>720kDa in native gel, to approximately 340kDa (Fig.S3C, right), revealing cancer-specific signal, 
as well as an unspecific band at ~200kDa in both cancer and non-cancer samples. Increasing the 
incubation temperature has a detrimental effect on the cancer-specific species, with maximum 
differential achieved at 37
O
C. Inclusion of reducing agent further shifted the mobility of the 
cancer-specific signal to the expected position of 65-70 kDa (Fig.S3C, left). Notably, higher 
concentrations of reducing agent resulted in loss of CIZ1b signal (Fig.S3D,E). Taken together, 
these data suggest that the 65-70kDa entity is itself a complex that is resistant to standard SDS-
PAGE denaturing conditions (10 mM DTT) but not more aggressive treatments (500mM DTT), 
and that it is normally present within a higher order complex of 340kDa, which is itself released by 
SDS from a still bigger complex in excess of 720kDa (illustrated in Fig.2A). In fact, fractionation of 
plasma to enrich for the exosomal compartment differentially partitioned the 55kDa species 
(detected via exon 17) and 65-70kDa species (detected via 043), with the 65-70kDa species 
detected exclusively in the pellet, which is a complex fraction that includes exosomes 
(Fig.S4A,B).  
 
Identification These observations enable a two-step gel-purification strategy for the 65-70kDa 
CIZ1b band. First, the 340kDa species was isolated from two independent lung cancer patient 
plasmas (Fig.3A), followed by further separation in the presence of reducing agent (Fig.3B). The 
65-70kDa band corresponding to the cancer-specific western blot signal was excised and 
digested with either trypsin or Asp-N endoprotease, for identification by mass spectrometry (MS). 
For both enzymatic digestions and two patients, Mascot database searching returned a single 
significant identification (P<0.05), corresponding to Uniprot P02671; human fibrinogen alpha 
chain. The endogenous fibrinogen molecule is a hexameric glycoprotein with a pre-cleavage 
formula mass of 326kDa and relative mobility of ~340kDa, comprised of two sets of three different 
chains (α, β, and γ) of 67, 51 and 45kDa respectively (18).  
Notably, CIZ1b was not identified in the 65-70kDa band after digestion with either 
enzyme. To determine whether a diagnostic CIZ1b fragment could be observed by MS if present, 
a short synthetic CIZ1b peptide (b13) and long CIZ1b peptide (b66, Table S1) were digested with 
Asp-N, which generates the diagnostic fragment DEEEIEVRSR by cutting either side of the 
CIZ1b exon junction (Fig.S5A). The peptide was positively identified post digestion of b13 and 
b66 by MALDI-MS/MS, though at low intensity relative to other peptides in the digest (shown for 
b66 in Fig.S5B). Further analysis was performed by LC-MS/MS using both data dependent 
acquisition (DDA) and targeted selection reaction monitoring (SRM), which focused the analysis 
to cycle through fragmentation of the expected 2
+
 and 3
+
 ions of DEEEIEVRSR, excluding all 
other precursors, to maximize specificity and sensitivity for this analyte. DEEEIEVRSR was 
identified in both the DDA and SRM analyses, indicating that the diagnostic peptide is observable 
by MS when excised from chemically synthesized peptide (SRM chromatogram, Fig.S5C). 
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However, when the same peptide was spiked into normal human plasma to reconstitute CIZ1b 
(see later and Fig.S5D), the diagnostic DEEEIEVRSR peptide was not detected in the excised 
65-70kDa band (SRM chromatogram, Fig.S5C). Lack of identification could reflect: i) secondary 
modifications that alter the expected mass of the CIZ1b diagnostic peptide or impair enzymatic 
digestion, ii) the more abundant proteins in the sample, primarily fibrinogen alpha chain, causing 
ion suppression or iii) absolute abundance falling below the limit of detection for the 
instrumentation after the losses incurred from the PAGE and digestion steps. It should be noted 
that the peptide is highly acidic, which is likely to reduce ionization efficiency in positive-mode 
MS, so that even with SRM a small drop in abundance could fall below the limit of detection. We 
concluded that if we cannot reliably detect the spiked peptide at physiologically relevant levels we 
are unlikely to detect endogenous CIZ1b, and so followed alternative approaches. 
 
Epitope reconstitution In order to confirm that the 65-70kDa cancer-specific epitope does indeed 
contain CIZ1b sequences, we adopted an epitope reconstitution strategy. To achieve this a pair 
of synthetic peptides spanning the exon14/15 junction (CIZ1b13, and CIZ1a22 which includes the 
alternatively spliced intervening sequence, Table S1) were incubated with normal human plasma 
(Fig.3C), and the output compared to lung cancer patient plasma. The CIZ1b peptide, but not 
CIZ1a, generated 043 and 2B-reactive epitope of comparable mobility to the endogenous epitope 
(65-70kDa), which is far in excess of the relative molecular mass of free peptide and not present 
in either of the individual components of the reaction (peptide lanes 6, 7, or plasma lane 3). This 
suggests that CIZ1b peptide forms an SDS/DTT-resistant complex with a carrier protein in human 
plasma, recreating the CIZ1b biomarker recognised by 2B and 043. Since we did not detect a 
mobility difference between endogenous (cancer plasma lane 1) and reconstituted epitope, the 
data also imply that the CIZ1b fragment contributing to the 65-70kDa cancer-specific species is 
very short, in the order of 10-20 amino acids in length. Furthermore, individual molecules may not 
necessarily have uniform molecular boundaries, possibly accounting for the often-diffuse nature 
of the band (Fig.S1A).  
A molar equivalent of the much longer CIZ1b peptide (b66, Table S1) reconstituted 
reactive epitope less efficiently, and was detectable only by 2B (Fig.3C lane 2, and at higher 
concentration in Fig.S5D). With this peptide the reconstituted signal migrated with greater relative 
molecular mass, at ~80kDa, consistent with the increased size of the contributing peptide. 
Importantly, reconstituted CIZ1b epitope, like the endogenous epitope, resists standard 
denaturing SDS-PAGE conditions (10 mM DTT, 2% SDS, 90
o
C), but is dissociated by a more 
aggressive reducing environment (Fig.S3E). Taken together, the data suggest that, in vivo, the 
cancer-specific epitope is composed of a relatively short fragment of CIZ1 encompassing the 
exon14b/15 junction, mounted on fibrinogen alpha chain, which itself makes up most of the mass 
of the 65-70kDa species. To further confirm this, epitope reconstitution experiments were 
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performed with purified human fibrinogen (Fig.3D). For both antibodies, reactive epitope was 
generated at the mobility of fibrinogen complex (340kDa in non-reducing gels) and the specificity 
of the signal was confirmed by lack of reactivity with equivalent CIZ1a peptide. Direct ELISA 
using human fibrinogen complexed with molar equivalents of CIZ1a and CIZ1b peptides (Fig.3E) 
confirmed three things; i) the specificity of epitope reconstitution with peptide b13 over a22, ii) 
negligible signal with fibrinogen alone, and iii) greater reactivity when peptide is mounted on 
fibrinogen. Moreover, inclusion of the very short CIZ1b peptide b7 (Table S1) revealed 
differences between 2B and 043; 2B recognises b7 while 043 does not in a manner that is 
unrelated to the presence of fibrinogen. The existence of CIZ1b epitope in a complex with 
fibrinogen is consistent with our earlier observations that the biomarker is depleted from serum 
samples isolated from clotted blood (Fig.1C). Thus, future clinical evaluation and application of 
this biomarker must avoid serum samples, and ensure stable use of anticoagulants.  
 
CIZ1b immunoassay  Based on knowledge of the composition of CIZ1b biomarker, we designed 
a sandwich immunoassay format capable of quantitative detection in partially denatured plasma. 
Antigen capture with CIZ1b antibody 043 from 5 ul of plasma (Fig.S6A) and detection via 
fibrinogen alpha chain, generated a cancer-specific signal, illustrated with assay development set 
B, described in Methods. Specifically, results by western blot with 043 generated ROC AUC 
0.823 (P=0.0002) and by ELISA with 043 /anti-fibrinogen of 0.830 (P=0.0007, Fig.4A,B). Thus, 
the two methods generate very similar outcomes, and the data is significantly correlated 
(Fig.S6B).  
Set B, which represents patients with a wide range of conditions presenting at York 
Hospital respiratory medicine clinics, was also used to evaluate the contribution of the CIZ1b 
component of the assay, since fibrinogen alone has been reported to have some potential as a 
biomarker for lung cancer (19). Quantitative detection of fibrinogen in the linear range 
(Fig.S6C,D) returned some discriminatory capability across this set, though relatively poor ROC 
AUC of 0.628 (p=0.225). This is consistent with western blot evaluation of fibrinogen (Fig.S1B), 
which indicated little difference between lung cancer patients and those without malignant 
disease. Thus capture of CIZ1b is the element that contributes the majority of the cancer-
selectivity to this assay. We further tested the specificity of the configuration by analysing Set B 
after capture with 043, but substituting anti-fibrinogen detector antibody with anti-human IgG (Fig. 
4D). Results indicate no discrimination between patients and control plasmas, confirming that 
anti-fibrinogen is an informative detector reagent that specifically detects a cancer-selective 
complex retrieved via CIZ1b. Finally, measurement of total IgG levels across set B by direct 
ELISA (Fig.4E) was used to normalize the output generated by 043/fibrinogen, leading to a 
marginal improvement in discrimination and ROC AUC 0.845 (p=0.0002, Fig.4F). Thus, we report 
here a straightforward sandwich ELISA format suitable for high-throughput application on hospital 
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platforms, that can reliably quantify circulating CIZ1b biomarker, and which can be used to 
identify patients with early stage lung cancer.  
 
Discussion  Primary lung cancer remains the main cause of cancer death (1.3 million pa 
worldwide). Early detection of lung cancer is important because the only curative therapy today is 
surgical resection of early-stage tumours (20). Crucially, for patients whose lung cancers are 
detected at stage 1 the outcome is substantially better than average. For stage 1A non-small cell 
lung cancer (NSCLC), the 5-year survival is 58-73% and for stage 1B 43-58%. However, NSCLC 
is usually diagnosed later when outcomes are significantly worse (stage 2A 36-46%, stage 2B 25-
36%, stage 3A 19-24%, stage 3B 7-9%, stage 4 2-13% (21)).  Screening programs using chest X-
ray (CXR) or low-dose computed tomography (LDCT) can identify the disease at an early stage, 
and therefore have the potential to improve survival. The largest study concluded that a 
significant reduction (20%) in mortality can be achieved amongst high-risk populations by regular 
screening of pre-symptomatic individuals, however around a quarter of those screened were 
referred for invasive follow-up procedures to investigate suspicious imaging results, and around 
96% of these turned out to be false positive (22). Similar findings were made by an independent 
trial using a population-based questionnaire to identify high-risk individuals (23). Thus both the 
personal and economic costs of screening make stand-alone imaging strategies difficult to justify. 
Further refined patient selection criteria coupled with a non-invasive technology that can eliminate 
a substantial proportion of false positive results, could add impact to early detection initiatives, by 
reducing over-diagnosis and at the same time reducing demand for LDCT.  
Two potential technologies that could meet this need are breath analysis (24) and 
circulating biomarkers. A number of studies suggest candidate biomarkers, usually panels of 
tumour proteins (25),(26) or autoantibodies (27), and an associated risk index. There is also 
much exploration of circulating DNA, RNA and methylation (28). However, we know of no other 
publicly available data set that evaluates a single analyte blood-based biomarker on cohorts with 
stage 1 disease, with the degree of accuracy and stability seen for the CIZ1b biomarker (1). 
Furthermore, to-date none of the candidates have been validated on prospectively collected 
cohorts, or directly compared to LDCT. The present technology will facilitate such comparison for 
CIZ1b, by enabling high-throughput measurement on a hospital-friendly platform.  
Clinical biomarkers have been instrumental in reducing mortality in cancer patients (29), 
however lack of understanding of the capability of biomarker tests can result in inappropriate use 
and lead to over-investigation of disease that is incorrectly assumed to be malignant (30). 
Furthermore the value of some has been questioned especially in relation to their use in the initial 
diagnosis of cancer (29, 31). Lack of clarity usually arises when a marker is found in other 
pathologies or when, like PSA, it is not specific for neoplastic cells. While further investigation will 
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be required for CIZ1b we already know that it can distinguish between early stage malignant 
disease and non-malignant conditions that may appear similar at presentation (1).  
The CIZ1b epitope that we measure in the blood may be the residue of degraded 
circulating tumour cells, or it may be a biologically active form that is secreted by cells. In support 
of the second possibility, non-variant epitopes of CIZ1 are consistently detected in plasma from 
people with or without cancer indicating that presence in the blood is part of normal CIZ1 biology. 
Crucially, the CIZ1b form can be robustly measured in microliter quantities of plasma suggesting 
that it is not a rare protein in lung cancer patients. Moreover, it is an exceptionally stable analyte, 
which is a fundamental requirement for any biomarker in routine clinical use. By definition, 
nuclear matrix proteins (those that remain in the residual nucleus after extraction of chromatin, 
RNA, lipids and salt-sensitive proteins) are highly stable entities. CIZ1 is part of this fraction (3) 
though it is also detected as punctate staining in the cytosol, and in some cell types decorating 
the plasma membrane (unpublished).  
The finding that CIZ1b epitope is part of a dramatically truncated fragment of CIZ1 that is 
stably associated with fibrinogen is unexpected. While it is documented that certain bacterial 
proteins, such as extracellular fibrinogen-binding protein (Efb) of S. aureus (32), can impact on 
fibrinogen-dependent platelet aggregation, it is not known at this point whether CIZ1b fragment 
has any impact on functionality, though the long CIZ1 peptides used here (b66, a74) do share 
some similarity with the consensus binding sequence of Efb. While a state of hypercoagulability is 
well-known to be associated with malignancy including primary lung cancers (33), the effect of 
CIZ1b remains to be investigated.  
A number of retrospective studies have suggested that fibrinogen levels may offer 
information that can be used to identify or monitor the course of disease, for example as part of a 
panel of analytes involved in haemostasis and angiogenesis in breast cancer patients (34), or via 
measurement of fibrinogen in urine samples from bladder cancer patients (35). Moreover, a 
recent study of 84,000 individuals that looked for elevation of three inflammatory biomarkers 
(CRP, fibrinogen and leukocyte count) observed an increased risk of colorectal, lung and breast 
cancer, with greatest risk associated with elevation of all three (19). While we were not able to 
observe elevated fibrinogen by western blot in our cohorts, ROC AUCs for ELISA output for Set B 
did suggest some information content with respect to discrimination of the patients with confirmed 
cancer, though this was not statistically significant and is unlikely to provide sufficient 
discriminatory power on its own. 
In summary, the data presented here and previously (1) show that CIZ1b is a strong 
candidate cancer-specific, single marker capable of identifying early stage lung cancer within at-
risk groups, without resort to invasive procedures. The technological developments now reported 
bring a low-cost, minimally invasive and accurate blood test a step closer, with potential to 
significantly improve lung cancer survival by improving early detection rates.  
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Methods   
Please see supplemental methods for details of plasma sets A and B, gels and sample 
preparation conditions, epitope reconstitution and mass spectrometry. 
Antibodies for western blot  CIZ1b was detected using positively and negatively affinity purified 
anti-peptide rabbit pAb 2B (1), or newly developed reagent 043 protein A fraction. CIZ1 exon 17 
was detected with a goat pAb against peptides in human exon 17 (Table S1) or NB74624, and 
exon 8 with NB74623 (both Novus Biologicals). Plasminogen was detected with Ab98262 
(Abcam) and fibrinogen with goat pAb F8512 (Sigma) or mouse mAb 120-10068 (Novus 
Biologicals).  
Enzyme linked immunosorbent assays  CIZ1b-fibrinogen alpha chain complex was detected by 
sandwich ELISA after partial denaturation of 5 ul of plasma in 100 ul of 0.5% tween20, 1% SDS in 
PBS, supplemented with 0.5mM PMSF and incubation at 20
O
C for 30 mins with repeated 
vortexing. Plates (Nunc Maxisorb 442404) were coated with 1ug of 043 CIZ1b pAb protein A 
fraction (Pierce 20356), overnight at 4
O
C in 100ul of 50 mM carbonate pH 9.6, then blocked for 
two hours at room temperature with 300 ul of filtered 1% BSA (Jackson ImmunoResearch 
1000162) in PBS. After three washes in 300 ul of 0.05% tween20 in PBS, analyte was added for 
2 hours at room temperature with gentle shaking. After fives washes, captured complex was 
detected with sheep anti-fibrinogen pAb (AF4786 R&D systems) followed by anti-sheep HRP 
(Jackson ImmunoResearch 213-032-177), and results developed using 100 ul Sure Blue (KPL 
520001) with detection at A450nm using a FLUOstar OPTIMA plate reader (BMG Labtech). For 
measurement of fibrinogen capture antibody was chicken IgY (1ug/well, Genway 15-288-22856), 
and analyte concentration was reduced five orders of magnitude by serial dilution. For 
measurement of human IgG in direct ELISA, 0.5 ul of plasma was coated directly onto plates in 
100ul of 50 mM carbonate buffer pH 9.6, blocked, washed and detected with anti-IgG (Jackson 
Immuno Research 709-035-149). For direct ELISA of synthetic analyte, 0.5ug purified fibrinogen 
(Sigma F3879) complexed with 100pmol peptide was coated onto plates in 100ul of 50 mM 
carbonate pH 9.6 as above, probe with 043 or 2B and detected with anti-rabbit HRP (Jackson 
ImmunoResearch). 
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Figure Legends 
Fig. 1 Exon junction specific antibodies detect CIZ1b in lung cancer patient plasma. A) Map of 
CIZ1 translated exons showing alternative splicing of exon 14 to yield 14b (CIZ1b) by exclusion of 
the indicated 8 amino-acids (positions refer to NCBI Reference Sequence: NM_012127.2). Also 
shown are the location of epitopes detected with antibodies used in B. B) Western blot of 
representative plasma samples from a patient with NSCLC (LC) and normal control (N) after 
denaturation for SDS-PAGE, showing CIZ1b band at 65-70kDa in LC (red arrow) detected by 
CIZ1b antibodies 2B and 043, and a ‘generic’ CIZ1 antibody-reactive band at 55kDa in both N 
and LC, detected via epitopes in exon 8 and exon 17. Also indicated is fibrinogen alpha chain. C) 
Comparison of CIZ1b levels in paired plasma (P) and serum (S) samples from four individuals 
analysed with CIZ1b antibody 2B. Histogram shows quantified band intensities for the 65-70kDa 
and 55kDa entities, derived from triplicate samples, with standard deviation. Note that serum 
lacks the 65-70kDa CIZ1b band. D) Model showing the simplest interpretation of the data in B, 
though extensive alternative splicing and likely secondary modification mean that the exact 
identity of the 55kDa entity in plasma is unverified. E) Receiver operating characteristic (ROC) 
curves showing area under the curve (AUC) values for 2B and 043 western blot results on lung 
cancer test set A. Dot plot shows correlation between the two date sets (LC samples are orange). 
Thresholds (black dotted lines) are set at the mean of non-cancer samples in the set, plus one 
SD. These yield sensitivity/specificity estimates for this set of 20 lung cancer and 20 non-cancer 
samples of: 2B, 85/67.5; 043, 90/77.5. Using an arbitrary threshold specified by both antibodies 
(see SI Data set 1) these are 90/87.5.  
 
Fig. 2 Deconstruction of CIZ1b biomarker and immunoassay design A) Schematic of results 
shown in Fig.S3, illustrating the complexity of the native complex in which CIZ1b epitope (red bar) 
resides in plasma, and the disrupting effect of detergent and reducing agents. Under native 
conditions CIZ1b is part of a complex in excess of 720 kDa, most likely encompassed within lipid 
vesicles (dotted circle, see also Fig.S5). SDS shifts the epitope to 340kDa, and reducing agents 
shift it further to the mobility typically observed in standard SDS-PAGE gels (65-70kDa). In the 
presence of excess reducing agent the western blot epitope is lost for both 2B and 043 CIZ1b 
antibodies. B) Schematic of sandwich ELISA format based on information summarised in A. 
 
Fig. 3 Reconstitution of CIZ1b biomarker from purified components  A) Two independent lung 
cancer patient plasmas were separated after incubation with 1% SDS (no reducing agent), in 
order to isolate the 340kDa band from stained gels (left). Band identity was verified by ponceau S 
stain followed by Western blot with anti-CIZ1b antibody 043 of a parallel gel (right). B) Gel slices 
were soaked in 2% SDS-PAGE loading buffer (with 200 mM ME) and separated through a 
denaturing gel to recover the 043-reactive species at 70kDa. Note that sample loaded as a gel 
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slice is slightly retardation compared to markers which are loaded in solution. Coomassie blue 
staining revealed 5 dominant bands including one at 70 kDa, which was isolated and digested 
with either trypsin (cancer plasma 1, C1) or AspN (cancer plasma 2, C2). C) Western blot of 
normal human plasma (non-cancer, N) showing reconstitution of CIZ1b epitope via complex 
formation between a carrier protein in plasma and synthetic CIZ1b peptides of the indicated 
lengths, but not equivalent CIZ1a peptide (Table S1). Note that free peptides migrate in reducing 
SDS-PAGE with a relative mobility 3 times expected (~21 kDa instead of 7.6kDa for b66, ~5kDa 
instead of 1.6 for b13, see Fig.S4C). None are recognized by CIZ1b antibodies in western blot 
unless complexed with carrier protein. For CIZ1b66 peptide a new reactive species is created at 
~80kDa (see also Fig.S4C), while CIZ1b13 peptide increases antigenicity at the same mobility as 
the endogenous epitope in lung cancer plasmas (C, lane 1). D) Western blot of non-reducing 
SDS-PAGE gel showing purified fibrinogen (6nmols) in all lanes (upper), with and without prior 
incubation with 100 pmols of the indicated peptides (Table S1), probed with CIZ1b antibodies as 
indicated. Under non-reducing conditions fibrinogen migrates with apparent molecular weight of 
~340kDa and this co-migrates with CIZ1b signal. E) Direct ELISA showing mean A450nm 
(triplicate analysis with SEM) generated by CIZ1b antibodies 2B or 043 as indicated, using molar 
equivalents of preformed peptide/fibrinogen complex as analyte, as described in Methods. ** T 
test p<0.05. 
 
Fig. 4 Immunoassay validation using lung cancer plasma and controls in development set B 
(n=39 non-cancer, 13 lung cancer). A) CIZ1b western blot with antibody 043. B) Sandwich ELISA 
format for CIZ1b antigen in plasma, using 043 capture antibody and anti-fibrinogen detector 
antibody. Comparison of the two data sets is in Fig.S6B) C) Quantitative detection of fibrinogen in 
the same samples using paired fibrinogen antibodies (calibration is in Fig.S6C). D) Substitution of 
anti-human IgG for anti-fibrinogen in a sandwich format similar to that shown in B. E) Detection of 
IgG in plasma by direct ELISA. F) Normalization of the data in C against the data in G. In all 
cases, receiver operating characteristic curves (ROC) indicate the relationship between true 
positive and false positive fraction (black points) and 95% confidence interval of the fitted ROC 
curve (grey points), and area under the curve (AUC) values in bold. Box and whisker plots display 
minimum and maximum, lower, median, and upper quartile, and outliers. 
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Highlights 
 
 CIZ1b is a promising blood biomarker for early detection of lung cancer  
 
 CIZ1b biomarker is a CIZ1 fragment that spans a cancer-specific exon boundary  
 
 CIZ1b fragment is complexed with fibrinogen alpha chain in cancer patient plasma  
 
 A sandwich immunoassay for complex can measure levels in cancer patient plasma 
 
 Stability and specificity make it suitable for routine detection of lung cancer 
